Illumina (ILMN) news
Recent news
S&P assigns Illumina 'A-2' S-T RTG; prop CP rated 'A-2'
S&P Global Ratings has assigned Illumina, Inc. an 'A-2' short-term rating for its commercial paper (prop CP), reflecting the company's strong liquidity position and financial stability. The rating underscores S&P's confidence in meet its short-term obligations without significant risk. Illumina, a…
AInvest Wire · 14h agoIllumina launches Bioinsight platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
AInvest Wire · 17h agoFitch assigns Illumina 'F2' short-term IDR, CP rating
Fitch Ratings has assigned Illumina, Inc. a 'F2' short-term issuer default rating (IDR) and a 'CP' commercial paper rating, reflecting the company's strong liquidity position and stable financial profile. The ratings underscore Fitch's confidence in Illumina's ability to meet its short-term…
AInvest Wire · 1d agoIllumina - CP program limit set at $1 bln aggregate principal amount - SEC filing
Illumina Inc. has announced the establishment of a commercial paper (CP) program with a limit set at an aggregate principal amount of $1 billion, as disclosed in a recent SEC filing . The program is intended to provide the company with a flexible and cost-effective source of short-term financing to…
AInvest Wire · 1d agoVaccine Products stocks rose in regular trading, with Moderna up 8.98%, Illumina gaining 3.13% and ZTS rising 1.59%.
AInvest Wire · 5d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.